Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connection™: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers?

Release Date: August 30, 2020
Expiration Date: August 30, 2021

Activity Overview

Small cell lung cancer (SCLC) is an aggressive form of the disease that comprises 15% of all new lung cancer cases diagnosed each year. Outcomes for patients with SCLC are poor with a median survival of less than 1 year. However, there have been recent advances in our understanding of resistance mechanisms and immune pathways in SCLC, and treatment strategies are being actively investigated in clinical trials for this disease. This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Medical Crossfire®: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers? live webcast held in June 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with lung cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

 

Acknowledgment of Commercial Support.

This activity is supported by an educational grant from AstraZeneca.
.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward the ASCO audience, primarily medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Apply efficacy and safety data from recent trials with immunotherapy in patients with SCLC in multiple lines of therapy
  • Discuss strategies to mitigate and manage immune-related adverse events in patients with SCLC
  • Evaluate immunotherapeutic approaches in conjunction with combined modality therapy for patients with limited-stage SCLC
  • Assess biomarkers and techniques in development to optimize selection of patients with SCLC for immunotherapy

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Anne Chiang, MD, PhD
Anne Chiang, MD, PhD
Associate Professor of Medicine
Chief Network Officer
Deputy Chief Medical Officer
Smilow Cancer Care Network
Yale School of Medicine
New Haven, CT
 

Disclosures: Grant Research Support: AbbVie Inc, Amgen Inc, AstraZeneca plc, Bristol Myers Squibb Co; Consultant: AstraZeneca plc; Other: Advisory board: AstraZeneca plc, Genentech Inc/F. Hoffman-La Roche Ltd, Jazz Pharmaceuticals plc

Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
 

Disclosures: Grant Research Support: AstraZeneca plc, Eli Lilly and Company, Genentech Inc/F. Hoffman-La Roche Ltd, Merck & Co Inc; Consultant: AbbVie Inc, ARMO BioSciences Inc, AstraZeneca plc, Biodesix Inc, Bolt Biotherapeutics Inc, Bristol Myers Squibb Co, Cybrexa Inc, Eli Lilly and Company, EMD Serono Inc, Genentech Inc/F. Hoffman-La Roche Ltd, Genmab A/S, Halozyme Inc, Heat Biologics Inc, I-MAB Biopharma Co Ltd, Immunocore Ltd, Infinity Pharmaceuticals Inc, Loxo Oncology Inc, Merck & Co Inc, Mirati Therapeutics Inc, Nektar, Neon Therapeutics, NextCure Inc, Novartis AG, Pfizer Inc, Sanofi SA, Seattle Genetics Inc, Shire plc, Spectrum Pharmaceuticals Inc, Symphogen A/S, Takeda Pharmaceutical Co Ltd, Tesaro, Tocagen Inc; Other: Board member: Junshi Biosciences Co Ltd

Leora Horn, MD, MSc
Leora Horn, MD, MSc
Associate Professor of Medicine
Assistant Vice Chairman for Faculty Development
Clinical Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN

 

Disclosures: Consultant: Boehringer Ingelheim GmbH, Bristol Myers Squibb Co, Xcovery LLC, Amgen Inc, AstraZeneca plc, EMD Serono Inc, Incyte Corporation, Merck & Co Inc, Pfizer Inc, F. Hoffman-La Roche-Genentech Inc, Xcovery LLC

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD
Chief, Thoracic Oncology Service
Codirector, Druckenmiller Center for Lung Cancer Research Sylvia Hassenfeld
Chair in Lung Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

 

Disclosures: Grant Research Support: Xcovery LLC, Bristol Myers Squibb Co, Boehringer Ingelheim Pharmaceuticals Inc; Consultant: AstraZeneca plc, Amgen Inc, EMD Serono Inc, Incyte Corporation, Genentech Inc, Pfizer Inc, Xcovery LLC; Other: Travel support – Xcovery LLC.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By